Stephen Aherne
Strategy& Deals and Valuations Partner, PwC United Kingdom
With over 20 years’ experience at PwC as a valuation and strategy consultant, Stephen brings experience of working with leading pharma and life sciences businesses in the UK and globally.
As UK Pharma and Life Sciences leader, he is at the forefront of PwC’s support for the industry, leading discussions with business leaders, innovative emerging companies and investors across the various sub-sectors.
Stephen helps companies at a global and local level understand and assess the value of their businesses and assets, the implications of potential strategic options and the opportunities for value creation and growth. His deep commercial, technical and scientific insights help clients to identify the value drivers across a broad base of areas including, drug products, consumer healthcare, pharma services, diagnostics and devices, and innovative biotech.
The industry has been at the forefront of the global pandemic response. Stephen has been supporting companies as they navigate the challenges and demands of this highly uncertain global phenomenon; from understanding how to value companies in times of volatility, as well as considering the appropriate strategic options in the face of an unpredictable business environment.
